Agios Pharmaceuticals Inc (AGIO)
44.78
-0.09
(-0.20%)
USD |
NASDAQ |
Nov 04, 16:00
43.78
-1.00
(-2.23%)
After-Hours: 05:51
Agios Pharmaceuticals Enterprise Value: 1.549B for Nov. 4, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 04, 2024 | 1.549B |
| November 01, 2024 | 1.554B |
| October 31, 2024 | 1.529B |
| October 30, 2024 | 1.636B |
| October 29, 2024 | 1.666B |
| October 28, 2024 | 1.623B |
| October 25, 2024 | 1.567B |
| October 24, 2024 | 1.566B |
| October 23, 2024 | 1.523B |
| October 22, 2024 | 1.583B |
| October 21, 2024 | 1.599B |
| October 18, 2024 | 1.590B |
| October 17, 2024 | 1.512B |
| October 16, 2024 | 1.487B |
| October 15, 2024 | 1.392B |
| October 14, 2024 | 1.349B |
| October 11, 2024 | 1.427B |
| October 10, 2024 | 1.380B |
| October 09, 2024 | 1.327B |
| October 08, 2024 | 1.305B |
| October 07, 2024 | 1.310B |
| October 04, 2024 | 1.352B |
| October 03, 2024 | 1.308B |
| October 02, 2024 | 1.378B |
| October 01, 2024 | 1.417B |
| Date | Value |
|---|---|
| September 30, 2024 | 1.529B |
| September 27, 2024 | 2.025B |
| September 26, 2024 | 2.164B |
| September 25, 2024 | 2.220B |
| September 24, 2024 | 2.081B |
| September 23, 2024 | 2.034B |
| September 20, 2024 | 2.078B |
| September 19, 2024 | 2.126B |
| September 18, 2024 | 2.021B |
| September 17, 2024 | 2.030B |
| September 16, 2024 | 2.014B |
| September 13, 2024 | 2.086B |
| September 12, 2024 | 1.986B |
| September 11, 2024 | 1.951B |
| September 10, 2024 | 1.963B |
| September 09, 2024 | 1.929B |
| September 06, 2024 | 1.892B |
| September 05, 2024 | 1.936B |
| September 04, 2024 | 1.976B |
| September 03, 2024 | 1.975B |
| August 30, 2024 | 2.042B |
| August 29, 2024 | 2.039B |
| August 28, 2024 | 2.011B |
| August 27, 2024 | 2.109B |
| August 26, 2024 | 2.080B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
11.17M
Minimum
Jun 14 2022
3.415B
Maximum
Feb 11 2021
1.355B
Average
1.045B
Median
Sep 15 2021
Enterprise Value Benchmarks
| Pfizer Inc | 219.16B |
| Regeneron Pharmaceuticals Inc | 83.27B |
| Ligand Pharmaceuticals Inc | 1.785B |
| ADMA Biologics Inc | 4.497B |
| AnaptysBio Inc | 196.54M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 947.92M |
| Revenue (Quarterly) | 8.964M |
| Total Expenses (Quarterly) | 111.78M |
| EPS Diluted (Quarterly) | 16.22 |
| Gross Profit Margin (Quarterly) | 91.27% |
| Earnings Yield | 25.37% |
| Normalized Earnings Yield | -14.05 |